Analysis of the Structural Diversity of Heterocycles amongst European Medicines Agency Approved Pharmaceuticals (2014–2023)
Key Points
The diversity of heterocycles is significant in new active substances approved by the EMA.
This analysis spans medicines approved from 2014 to 2023, showcasing structural variation.
Heterocycles contribute greatly to the complexity of pharmaceutical compounds in this period.
Understanding heterocycle diversity aids in the development of innovative pharmaceuticals.
Abstract
This review presents a detailed analysis of the heterocycle diversity amongst medicines with new active substances (NAS) approved by the European Medicines Agency in the last 10 years (2014–2023). A...